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SpleenAbstract Considering that lead caused a lot of health problems in the world, the present study was
carried out to investigate the protective effect of captopril as antioxidants to reduce liver and spleen
toxicity induced by lead. Animals were divided into 3 groups, the 1st group served as control group,
the 2nd group received 20 mg/kg of lead acetate and the 3rd group received 50 mg/kg of captopril
one hour prior to lead administration for 5 days. Results showed that lead intake caused severe
alterations in the liver and spleen manifested by hepatocytes degeneration, leukocytic infiltration,
fibrosis in liver and moderate to severe liver pathological score. Spleen showed ill-defined architec-
ture, presence of large macrophages and lymphoid necrosis. Administration of captopril reduced
hepatotoxicity, liver fibrosis and decrease in pathological scoring system. Moreover, reduced toxi-
city in spleen is represented by reduction in necrotic areas, more or less healthy lymphoid follicles
and decreasing in pathological scoring system.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lead is a naturally occurring bluish-gray metal found in small
amounts in the Earth’s crust and can be found in all parts ofour environment (Gupta, 2007). Lead is found in our food,
water, air and soil. Lead emitted by smelters and boilers that
burn used motor oil is frequently deposited in the soil, where
it is taken up by crops (Chiras, 2009). Lead is known as an
enzymatic toxicant, is neurotoxic, hemato and cardiovascular
toxic, nephrotoxic, immunotoxic, carcinogenic, teratogenic
and mutagenic (Kiran et al., 2009; Moreira and Moreira,
2004). Lead damages cellular materials, alters cellular genetics
and produces oxidative damage. It causes hyperproduction of
free radicals and decreased availability of anti oxidant reserves
to respond to the resultant damage. It also interrupts enzyme
activation and competitively inhibits trace mineral absorption.
Lead binds to sulfhydryl proteins (interrupting structural pro-
tein synthesis), alters calcium homeostasis and lowers the levels
Table 1 Liver and spleen index in control, lead and lead
treated with captopril groups.
Index Control Lead Lead and captopril
Liver index 6.4 ± 0.2 8.04 ± 0.8 5.9 ± 0.6
Spleen index 0.65 ± 0.09 0.8 ± 0.1 0.72 ± 0.08
Data =Mean ± SEM (standard error of means).
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(Lynpatrick, 2006). The toxicity of lead is closely related to
age, sex, route of exposure level of intake, solubility, metal oxi-
dation state, retention percentage, duration of exposure, fre-
quency of intake, absorption rate, mechanisms and efficiency
of excretion. Lead has been associated with various forms of
cancer, nephrotoxicity, central nervous system effects and car-
diovascular diseases in humans (Pitot and Dragan, 1996).
Captopril (D-3-mercapto-2-methyl-propanoyl-L-proline) is
an angiotension-converting enzyme (ACE) inhibitor. Besides,
its role as a treatment for hypertension (Sultana et al., 2007),
it is commonly used as a cardioprotective drug (Khattab
et al., 2005). Like other ACE inhibitors, captopril inhibits
the conversion of angiotensin I, a relatively inactive molecule,
to angiotensin II which is the major mediator of vasoconstric-
tion and volume expansion induced by the renin–angiotensin
system. Captopril, an inhibitor of angiotensin converting
enzyme (ACE), has also been postulated as a free radical scav-
enger because of its terminal sulfhydryl group (Bagchi et al.,
1989; Andreoli, 1993). Some in vitro studies indicate that cap-
topril functions as an antioxidant both by scavenging ROS and
by increasing the activities of antioxidant enzymes such as
superoxide dismutase and glutathione peroxidase (Westlin
and Mullane, 1988; Kojsova et al., 2006). Captopril has been
shown to decrease serum lipid peroxide concentrations in dia-
betic patients (Ha and Kim, 1992).
Therefore, the aim of the present work is to evaluate the
possibility of reducing toxic effects induced by lead in the liver
and spleen by captopril and investigate its antifibrotic effects.
2. Material and methods
2.1. Design of experiment
Thirty male Swiss albino mice (25 ± 3 g) Mice were housed in
polypropylene cages inside a well-ventilated room at 22 ± 1 C
and 12-h periods of light and dark, with free access to clean
water and commercial mice food The experiments were
approved by state authorities and followed Saudi Arabian
rules for animal protection.
Mice were randomly divided into three groups, ten mice per
each group. First group served as control group received sal-
ine, second group received oral administration of 20 mg/kg
of lead acetate by gavage, and third received oral administra-
tion of 50 mg/kg of captopril one hour prior to administration
of 20 mg/kg of lead acetate for five days, All animals were sac-
rificed one day-post to the end of experiment.
2.2. Liver and spleen index
At the end of the experimental period, eachmouse was weighed,
liver and spleen were then removed and weighed. Finally, the
liver and spleen indices were calculated by dividing the weight
of liver or spleen by the body weight and then multiplying by
100 and the results were statistically analyzed by SPSS 16.
2.3. Histopathological analysis
2.3.1. Histological preparation
Livers and spleens were collected and cut into small pieces,
fixed in 10% neutral buffered formalin. Following fixation,specimens were dehydrated, embedded in wax, and then sec-
tioned to 5 lm thickness. Sections were stained with hema-
toxylin and eosin. Also, other sections were stained with
Masson trichrome stain according to Drury and Wallington
(1980).
2.3.2. Pathological scoring system for changes in liver and spleen
architecture
Liver sections stained with HE were examined for pathological
score of the following criteria: ballooning, inflammation,
apoptotic cells and fibrosis. Scoring values were registered
according to Table 2. Spleen sections were examined for
pathological score of the following criteria: lymphoid necrosis
and red pulp expansion and scoring values registered accord-
ing to Table 2 (Klopfleisch, 2013).
2.3.3. Spleen lymphoid follicle analysis
Lymphoid follicles areas were measured by microscope mea-
surement system (Motic-2000) in 20 different fields per section,
the number of macrophages in peri-outer zone of follicles was
counted 200xfield and areas of macrophages were measured by
microscope system.
2.4. Statistical analysis
A one-way ANOVA was carried out, and the statistical com-
parisons among the groups were performed with Duncan’s test
using a statistical package program (SPSS version 16.0). All P
values are two-tailed and P< 0.05 was considered as signifi-
cant for all statistical analyses in this study.
3. Results
3.1. Liver and spleen index
Liver index of mice group receiving lead acetate showed an
insignificant increase compared to the control group, whereas
the mice group receiving lead acetate and captopril showed
insignificant differences compared to the control group
(Table 1) and insignificant decrease compared to the group
receiving lead acetate only. Spleen index of mice group
received lead acetate and the other one received lead acetate
and captopril showed insignificant increase compared to con-
trol group (Table 1).
3.2. Histopathological analysis
3.2.1. Histological examination
3.2.1.1. Liver. Non-treated mice liver served as control investi-
gated for the purpose of comparison showed the normal struc-
Table 2 Scoring criteria for the evaluation of histopatholog-
ical changes in liver architecture and in spleen architecture.
Changes in liver architecture
Ballooning degeneration
Score 0 No ballooning degeneration
Score 1+ Minimal enlargement in few hepatocytes
Score 2+ Mild enlargement in many hepatocytes
Score 3+ Moderate enlargement in most hepatocytes
Score 4+ Severe enlargement in most hepatocytes
Inflammation
Score 0 No inflammatory foci
Score 1+ 1 inflammatory foci per 200 hpf
Score 2+ 2–4 inflammatory foci per 200 hpf
Score 3+ >4 inflammatory foci per 200 hpf
Apoptotic cells
Score 0 No apoptotic cells
Score 1+ Few apoptotic cells
Fibrosis
Score 0 No fibrosis
Score 1+ Portal/sinusoidal minimal fibrosis
Score 2+ Portal/sinusoidal mild fibrosis
Score 3+ Bridging fibrosis
Score 4+ Cirrhosis
Changes in spleen architecture
Lymphoid necrosis
Score 0 No necrotic foci
Score 1+ <5% necrotic foci per 200 hpf (mini)
Score 2+ 5–25 necrotic foci per 200 hpf (mild)
Score 3+ 25–50 necrotic foci per 200 hpf (moderate)
Score 4+ >50% necrotic foci per 200 hpf (severe)
Red pulp expansion
Score 0 No expansion
Score 1+ Minimal expansion
Score 2+ Mild expansion
Score 3+ Moderate expansion
Score 4+ Severe expansion
Figure 1 Photomicrograph of control mice liver showed normal
liver consists of central vein and hepatocytes (H&E-100).
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central vein in the center of the lobule, hepatic cells were
arranged in strands, blood sinusoids in between the hepatic
cells and portal canals at the periphery of hepatic lobules.
The portal canal comprises branches of the portal vein, hepatic
artery and bile duct, often also with a lymphatic vessel lying in
a small amount of connective tissue (Fig. 1).
Livers of mice received oral administration of 20 mg/kg/bw
of lead acetate showed marked changes in the hepatic tissue
represented by congested central veins, dilatation in blood
sinusoids with abundant kupffer cells, hepatic cells suffered
from degeneration, its nuclei looked swollen and some of them
have fragmented chromatins, whereas others showed absence
of chromatin (Fig. 2a). Other sections of treated liver mice
with lead acetate showed large aggregations of leukocytic infil-
tration (Fig. 2b), moreover, appearance of precipitation of col-
lagenous fibers around bile duct stained blue by
Masson’trichrome (Fig. 2c).
Livers of mice treated with captopril before oral adminis-
tration of lead acetate revealed healthier sections compared
with previous groups represented by more or less healthy hep-
atic cells with darkly stained nuclei, binucleated cells appearedas an evidence of regeneration, kupfer cells and scattered
leukocytes were abundant in the sinusoids. Some sections
showed dilated vein surrounded by leukocytic infiltration
and some necrotic foci (Fig. 3a). Tissues stained by Trichrome
showed small bundles of collagenous fibers were present in the
liver tissue, it was obvious that captopril had antifibrotic effect
(Fig. 3b).
3.2.1.2. Histopathological scoring system of liver. Non-treated
control mice livers scored (0) normal pathological system,
whereas, liver sections of mice received lead acetate scored
moderate ballooning in hepatocytes (3), severe inflammation
(3), presence of apoptotic cells (1) and mild fibrosis (2). More-
over, liver sections of mice treated with captopril prior to lead
acetate scored minimum ballooning in hepatocytes (1), mini-
mum inflammation (1), no apoptotic cells (0) and minimum
fibrosis (1) (Table 3). Scoring system of liver revealed that
group treated with captopril prior to lead acetate showed
decrease in pathological score system compared to group
receiving lead.
3.2.1.3. Spleen. Non treated spleen sections showed normal
spleen structure composed of white pulp and red pulp, besides
to the fibrous capsule which covered the spleen. White pulp
consisting mainly of B-lymphocytes was arranged into two
zones, marginal zone (outer rim of loose lymphocytes) that
contains macrophages, and mantle zone (inner rim of lympho-
cytes). The red pulp is the area of spleen in between white pulp
and consists of open sinuses and cellular cords (Fig. 4).
Spleen of mice receiving lead acetate showed marked
changes represented by distorted spleen architecture, that it
was ill-defined due to diffusion of white pulp into the red pulp
in addition to the appearance of necrotic foci, large macro-
phages were seen in the tissue with great numbers
(Fig. 5a and b).
Spleen of mice treated with captopril prior to receiving lead
acetate revealed a decrease in pathological alterations, to some
extent well-defined spleen architecture appeared but with diffu-
sion of red pulp into white pulp, few necrotic areas with scat-
tered basophils and neutrophils, also macrophages were
abundant (Fig. 6a and b).
Figure 2 (a) Photomicrograph of mice liver treated with lead
acetate showed congested and dilated central vein (cv), scattered
inflammatory cells (arrows) and complete degeneration of cell
nuclei (d) (H&E-Mag 400). (b) Photomicrograph of mice liver
treated with lead acetate showed aggregations of lymphocytic
infiltration (L) (H&E-Mag 400). (c) Photomicrograph of mice
liver treated with lead acetate showed blue stained layers of
collagenous fibers (F) surrounded dilated central vein (cv) (Mtr-
Mag 400).
Table 3 Pathological score for changes in liver architecture.
Items Control Lead Lead and captopril
Ballooning 0 3 ± 0.1 1 ± 0.2
Inflammation 0 3 ± 0.1 1 ± 0.1
Apoptic cells 0 1 ± 0 0 ± 0.1
Fibrosis 0 2 ± 0.2 1 ± 0.2
The data are expressed as mean ± SEM (standard error of mean).
Figure 3 (a) Photomicrograph of mice liver treated with
captopril before lead acetate treatment showed healthy central
vein (cv), binucleated cells (arrows) (H&E-Mag 400). (b)
Photomicrograph of mice liver treated with captopril before lead
acetate treatment showed small amounts of collagenous fibers
(arrows) stained with blue colour (Mtr-Mag 400).
670 B.A. Aldahmash, D.M. El-Nagar3.2.1.4. Histopathological scoring system of spleen. Non-treated
control mice spleen scored (0) normal score of spleen, whereas,
spleen sections of mice received lead acetate scored (4) severelymphoid necrosis and (3) moderate red pulp expansion.
Moreover, spleen sections of mice treated with captopril prior
to lead acetate scored (1) minimum lymphoid necrosis and (2)
mild red pulp expansion (Table 4). So, captopril prior to lead
decreased the pathological score of spleen compared to group
received lead only.
3.2.1.5. Lymphoid follicle analysis. Non-treated control spleen
sections showed lymphoid follicle area of (81 lm3). Spleen of
mice receiving lead acetate showed significant diminish
P< 0.05 in lymphoid follicle area (27 lm3) compared to con-
trol, whereas, spleen of mice treated with captopril prior to
lead acetate registered (80 lm3) insignificant differences com-
pared to control and a significant increase P< 0.05 compared
Figure 5 (a) Photomicrograph of mice spleen treated with lead
acetate showed lymphoid follicle with numerous necrotic foci
(arrows) filled by darkly stained neutrophils and basophils (H&E-
Mag 400). (b) Photomicrograph of mice spleen treated with lead
acetate showed congested and ill defined spleen architecture,
trabeculae (T) and large macrophages (arrows) (H&E-Mag 400).
Figure 6 (a) Photomicrograph of mice spleen treated with
captopril before lead acetate showed lymphoid follicle (LF)
without necrosis (H&E-Mag 400). (b) Photomicrograph of mice
spleen treated with captopril before lead acetate showed expansion
of red pulp and macrophages (arrows) (H&E-Mag 400).
Figure 4 Photomicrograph of control mice spleen showed
normal spleen consists of lymphoid follicles (arrows) called white
pulp, reddish areas consist of spleen parenchyma called red pulp
(H&E-Mag X100).
Table 4 Pathological score for changes in spleen architecture.
Items Control Lead Lead and captopril
Lymphoid necrosis 0 4 ± 0.1 1 ± 0.09
Red pulp expansion 0 3 ± 0 2 ± 0.1
The data are expressed as mean ± SEM (standard error of mean).
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showed insignificant differences among three experimental
groups (2, 3 and 3) in control, lead acetate and lead acetatetreated with captopril groups respectively. Macrophage area
in the non-treated control group registered (2.9 lm3), a signif-
icant increase P< 0.05 in macrophage area was registered
(8.5 lm3) in group receiving lead acetate compared to control
group, whereas, macrophage area in the group treated with
captopril prior to lead acetate registered (4 lm3) insignificant
increases compared to the control group and a significant
decrease P< 0.05 compared to the lead acetate group
(Table 5).
4. Discussion
Lead had been a toxic problem for human beings from the ear-
liest time. The ingested and absorbed lead stored primarily in
soft tissues and bone, but the highest concentration of lead
occurs within the bone, teeth, liver, lung, kidney, brain and
spleen (Plumlee, 2004; Mudipalli, 2007). The present study
Table 5 Spleen lymphoid follicle analysis showed area of lymphoid follicles, number of macrophages and area of macrophages in
spleens of control, lead and lead treated with captopril groups.
Items Control Lead Lead and captopril
Area of lymphoid follicles lm3 81 ± 1.3 27 ± 0.3*a 80 ± 1.3*b
Number of macrophages Cells/200field 2 ± 0.6 3 ± 0.2 3 ± 0.5
Area of macrophages lm3 2.9 ± 0.4 8.5 ± 1.02*a 4 ± 0.48b
The data are expressed as mean ± SEM (standard error of mean).
*a P< 0.05 significant difference compared to control group.
*b P< 0.05 significant difference compared to lead acetate group.
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between control and experimental lead groups, that run in
agreement with (Allouche et al., 2011). Histological investiga-
tions revealed that lead acetate exposure resulted in marked
changes in the liver these findings agreed with (Jankeer and
El-Nouri, 2009; Muselin et al., 2010; Suradkar et al., 2010)
they stated that rat exposure to lead acetate caused hepatotox-
icity characterized by engorgement of blood vessels along with
sinusoidal hemorrhage, infiltration, dilatation of central veins
and vacuolar degeneration of hepatocytes. In the present
study, lead reached the liver via the portal vein that the liver
is the first organ exposed to internally absorbed nutrients
and other xenobiotics so lead accumulated in the liver tissue
caused severe alterations characterized by congested and
dilated portal veins and degeneration in hepatic cells with
moderate ballooning, severe inflammation, apoptotic cells
and mild fibrosis. Most orally ingested lead is excreted, but a
portion is absorbed and is transferred to the blood where lead
binds to hemoglobin in the erythrocytes so lead is carried
through the circulatory system by erythrocytes, virtually all tis-
sues in the body can become exposed to the toxic metal, par-
ticularly hematopoietic and immune system (Goering, 1993;
Gidlow, 2004; Lawrence and McCabe, 1995). In the spleen,
phagocytes (macrophages and polymorphonuclear cells) are
responsible for slowing the propagation of an invading patho-
gen, while an antigen-specific adaptive immune response
(antibody- or cell-mediated) is being established. Lead was
reported to inhibit macrophage function (Kowolenko et al.,
l988; Mauel et al., 1989) possibly by overloading macrophages
with cellular debris and inhibiting macrophage production of
nitric oxide (Tian and Lawrence, 1995). In the context of adap-
tive humoral and cellular immune responses, lead increased
both B-cell and T-cell in vitro proliferation (Lawrence,
1981a–c; Warner and Lawrence, 1986; Razani et al., 1999).
In the present study, administration of lead resulted in severe
changes in the spleen represented by severe lymphoid necrosis,
moderate diffusion of white pulp into the red pulp, diminished
lymphoid follicles and appearance of large macrophages might
be due to the production of debris of dead cells.
Captopril is an angiotensin-converting enzyme inhibitor
that inhibits the ACE that catalyzes the conversion of angio-
tensin I to the vasoconstrictor peptide, angiotensin II. It is gen-
erally recommended for the treatment of hypertension,
congestive heart failure, acute myocardial infarction and renal
complications of diabetes mellitus. It also has beneficial exper-
imental effects in hindering the progression of chronic renal
failure, diabetic nephropathy and development of atheroscle-
rosis (Chobanian et al., 1990; Omata et al., 1996). Also there
is increasing evidence that the broader pharmacological prop-
erties of ACE inhibitors encompass the anti-oxidant abilitythrough scavenging free radical because of its terminal-SH
group in a variety of organ systems (Ghazi-Khansari et al.,
2006; Wang et al., 2000). The anti-oxidant activity of captopril
possibly ameliorates the oxidative stress. The –SH group in the
structure is a crucial requirement for free radical scavenging
activity but not the proline part (Chopra et al., 1992). The pre-
sent study proved that captopril could reduce the hepatotoxi-
city induced by lead that liver sections of mice received
captopril before lead treatment showed healthy liver sections
revealed by healthy hepatocytes and regeneration process with
minimum ballooning in hepatocytes, inflammation, fibrosis
and no apoptotic cells as recorded by pathological scoring sys-
tem, also the present results demonstrated the antifibrotic
effect of captopril that it diminished the collagenous fibers
compared with the previous groups, these findings agreed with
Amirshahrokhi et al. (2010) who suggested that captopril had
protective effect against hepatic fibrosis because of the ability
of captopril to reduce BDL-induced production of the proin-
flammatory cytokine – TNF-a which plays a major role in
the development of hepatic fibrosis. Also it increases the hep-
atic content of IL-10 in BDL rats. Interleukin-10 is an anti-
inflammatory cytokine and has an important role in the pre-
vention of hepatic inflammation and fibrosis. Moreover, cap-
topril has protective effects against spleen toxicity, it
protected lymphoid follicles from severe necrosis, diminishing
and decrease red pulp expansion.
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